{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:09Z","timestamp":1787595729402,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, multisystem thrombotic microangiopathy mediated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) autoantibodies. Immunosuppression with anti\u2010CD20 therapy is the mainstay of treatment. MabThera's patent has now expired and biosimilars have been approved. Eighty\u2010four consecutive patient episodes over 2\u00a0years, prior to and following our switch to Truxima are presented. Day 1 (D1), Day 28 (D28) and 3\u2010month platelet counts, ADAMTS13 activity, and CD19 levels, adverse reactions and infective complications were recorded. Platelet counts were not significantly different between acute MabThera and Truxima treatment (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.085, D28 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.77, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.71) and electively (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.79, D28 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.68, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.99). ADAMTS13 recovery also was not significantly different acutely (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.99, D28 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.27, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.26) and electively (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.59, D28 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.61, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.34). CD19% depletion at D1 and 3\u00a0months was not significantly different acutely (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.52, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.56) and electively (D1 <jats:italic>P<\/jats:italic>\u00a0=\u00a00.22, 3\u00a0months <jats:italic>P<\/jats:italic>\u00a0=\u00a00.19). Infusion reactions and infective complications were comparable with both therapies. This is the first series of the Rituximab biosimilar Truxima to be reported in iTTP, demonstrating equivalence to MabThera in terms of ADAMTS13 recovery, CD19 depletion, and platelet count at D28 and 3\u00a0months post\u2010administration, with comparable infusion and infective complications. The financial benefit of the biosimilar anti\u2010CD20 is considerable.<\/jats:p>","DOI":"10.1111\/bjh.15874","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:35:48Z","timestamp":1553776548000},"page":"912-917","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune\u2010mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-4625","authenticated-orcid":false,"given":"Matthew J.","family":"Stubbs","sequence":"first","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Low","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"McGuckin","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Newton","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"},{"name":"Department of Haematology UCLH and Cardiometabolic Programme\u2010NIHR UCLH\/UC BRC London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Westwood","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raakhee","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cheesman","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-6517","authenticated-orcid":false,"given":"Marie A.","family":"Scully","sequence":"additional","affiliation":[{"name":"Department of Haematology UCLH NHS Foundation Trust London UK"},{"name":"Department of Haematology UCLH and Cardiometabolic Programme\u2010NIHR UCLH\/UC BRC London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph7050530"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261893"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1359537"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.909"},{"key":"e_1_2_8_6_1","unstructured":"EMA. (2012)Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non\u2010clinical and clinical issues. EMA\/CHMP\/BMWP\/403543\/2010. European Medicines Agency London UK.https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guidelinesimilar-biological-medicinal-products-containing-monoclonal-antibodies-nonclinical_en.pdf"},{"key":"e_1_2_8_7_1","unstructured":"EMA. (2016)Assessment report: Truxima. International non\u2010proprietary name: rituximab (2016). Procedure No. EMEA\/H\/C\/004112\/0000. EMA\/CHMP\/75695\/2017. European Medicines Agency London UK.https:\/\/www.ema.europa.eu\/documents\/assessment-report\/truxima-eparpublic-assessment-report_en.pdf"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3762864"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0522-y"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30120-5"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199811000-00012"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06448.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09167.x"},{"key":"e_1_2_8_15_1","first-page":"824","article-title":"SAT0146 randomised double\u2010blind study shows comparable long\u2010term efficacy and safety between rituximab biosimilar CT\u2010P10 and innovator rituximab in patients with rheumatoid arthritis: 48\u2010week results","volume":"76","author":"Suh C.H.","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.06.007"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008268"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15874","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15874","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15874","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T12:07:04Z","timestamp":1694261224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bjh.15874"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15874","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"2018-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}